Lactate Dehydrogenase (LDH) is an enzyme that catalyzes the conversion of pyruvate, the end product of glycolysis, into lactate (and vice versa) with concomitant interconversion of NADH and NAD+.LDH is made up of two main subunits, LDH-A and LDH-B. These two subunits can combine to form LDH1, LDH2, LDH3, LDH4, and LDH5, one of five isoenzymes.
Due to its predominance in skeletal muscle, LDH-A is also known as the M subunit, and LDH-B is known as the H subunit due to its predominance in the heart. An essential metabolic enzyme called LDH-A has been linked to the growth, invasion, and metastasis of cancer. The main contributor to the Warburg effect is LDH-A. Multiple cancers' clinicopathologic traits and survival rates have been shown to correlate with LDH-A. LDH-A inhibition inhibits the proliferation of primary breast tumors. A vital glycolytic enzyme called LDH-B catalyzes the transformation of lactate and NAD+ into pyruvate, NADH, and H+. When it comes to autophagy in cancer cells, LDHB is crucial.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V73842 | Anticancer agent 121 | 2924532-47-6 | Anticancer agent 121 is a human lactate dehydrogenase A enzyme inhibitor (hLDHA) with good anti-cancer activity and may be utilized in antitumor research. |
|
V73847 | Anticancer agent 122 | 2924532-50-1 | Anticancer agent 122 is a human lactate dehydrogenase A enzyme inhibitor (hLDHA) with good anti-cancer activity and may be utilized in antitumor research. |
|
V77222 | AXKO-0046 dihydrochloride | AXKO-0046 di-HCl, an indole analogue, is a selective inhibitor of LDHB. | |
|
V73843 | CHK-336 | 2743436-86-2 | CHK-336 (Example 1) is an orally bioavailable LDHA inhibitor (IC50＜1 nM), which can inhibit lactate production in mouse hepatocytes. |
|
V73845 | D-Lactate dehydrogenase (D-LDH) | 9028-36-8 | D-Lactate dehydrogenase (D-LDH) is an oxidoreductase that uses NAD+ or NADP+ as an acceptor and acts on the donor CH-OH group. |
|
V21444 | FX11 | 213971-34-7 | FX-11 is a novel, potent and selective lactate dehydrogenase A (LDHA) inhibitor with anticancer activity. |
|
V73840 | GNE-140 racemate | 1802977-61-2 | GNE-140 racemate is a racemic mixture (racemate) of (R)-GNE-140 and (S)-GNE-140. |
|
V3951 | GSK2837808A | 1445879-21-9 | GSK2837808A is a potent, selective, andan NADH-competitiveinhibitor of lactate dehydrogenase A (LDHA) withIC50s of 1.9 and 14 nM for LDHA and LDHB, respectively. |
|
V73844 | LDHA-IN-3 | 227010-33-5 | LDHA-IN-3, a selenobenzene compound, is a potent, noncompetitive lactate dehydrogenase (LDHA) inhibitor (IC50=145.2 nM). |
|
V73846 | LDHA-IN-5 | 2776148-90-2 | LDHA-IN-5 is a novel, potent and dual GO/LDHA inhibitor for primary hyperoxaluria. |
|
V87531 | LDHA-IN-6 | LDHA-IN-6 (compound 6) is an orally available lactate dehydrogenase A (LDHA) bioactive inhibitor with IC50 of 46 nM. | |
|
V87533 | LDHA-IN-7 | LDHA-IN-7 (compound 21) is an orally active lactate dehydrogenase A (LDHA) and LDHB inhibitor with IC50 of 72 nM and 1.2 μM, respectively. | |
|
V73841 | MEDS433 | 2241027-61-0 | MEDS433 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH) with IC50 of 1.2 nM. |
|
V9332 | NHI-2 | 1269802-97-2 | NHI-2 is a novel, potent, selectiveandcell membrane permeable inhibitor of human lactate dehydrogenase isoform A (LDH-A; IC50 values 14.7 µM and 55.8 µM in a NADH competition assay for LDH-A and LDH-B, respectively), whcih is akey enzyme necessary to sustain glycolysis, the major pathway used by many cancer cells for cell growth and proliferation (the Warburg effect). |
|
V4547 | S-GNE-140 | 2003234-64-6 | S)-GNE-140, the S-enantiomer ofGNE-140, is a novel and potent lactate dehydrogenase (LDHA) inhibitor with less activity. |
|
V51407 | Nedosiran sodium (DCR-PHXC) | 2247026-22-6 | Nedosiran sodium (Rivfloza) is an RNA interference agent (RNAi) that can inhibit lactate dehydrogenase (LDH). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
